Deferasirox vs deferiprone (DFO)
SAEs ‐ thalassaemia‐related SAEs
It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).
1 finding from 1 review
- Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes onlyRR 0.95 [0.41, 2.17]2 studies · 247 participantsVery low